NEPHROS INC: directors' dealings · United States · SEC (Form 4)

About NEPHROS INC

Nephros, Inc. (ticker: NEPH) is listed on the Nasdaq market in the United States (United States) and operates as a specialist in water-filtration solutions for medical and commercial applications. For French-speaking investors, the company sits at the intersection of healthcare technology, regulated filtration products, and critical infrastructure rather than in traditional “pure-play” medtech. Its core value proposition is water safety: reducing contaminants and supporting sanitary requirements in sensitive environments such as hospitals, dialysis centers, and commercial facilities where water quality is operationally important. ([nephros.com](https://www.nephros.com/investors/?utm_source=openai)) Nephros was originally founded by health professionals, scientists, and engineers affiliated with Columbia University, with a historical focus on technology and products for end-stage renal disease therapy. Over time, the company evolved into a broader water-technology business. According to company disclosures, its headquarters, research, manufacturing, and distribution functions are concentrated in New Jersey, with facilities in South Orange and Whippany. This footprint gives the company tighter control over product development and delivery while keeping the organization relatively lean. ([fintel.io](https://fintel.io/doc/sec-nephros-inc-1196298-10k-2025-march-24-20171-4878?utm_source=openai)) From a business-model perspective, Nephros sells filtration products and related solutions across two main end markets: medical and commercial. In medical applications, the company serves infection-control and dialysis-related use cases, where reliability and regulatory compliance are essential. In commercial applications, the offering targets customers that require consistent water-quality management for safety, equipment protection, and operational continuity. Management also emphasizes an integrated approach combining products, service, and education, which points to a strategy aimed at building recurring relationships and customer retention rather than relying solely on one-time product sales. ([nephros.com](https://www.nephros.com/investors/?utm_source=openai)) Competitive positioning is that of a focused niche player. Nephros is not a global giant, but it differentiates itself through specialization in water filtration for critical environments, regulatory positioning, and a product set designed for high-stakes settings. Recent disclosures suggest that this strategy has been gaining traction: throughout 2025 and into early 2026, the company reported strong revenue growth, record programmatic sales, and expanding active-site counts. It also launched a new S100 in-line microfilter in 2025, which management described as extending the portfolio between microfiltration and ultrafiltration. ([nasdaq.com](https://www.nasdaq.com/press-release/nephros-announces-strong-third-quarter-financial-results-achieving-highest-level?utm_source=openai)) For investors, NEPH offers a combination of defensive end-market exposure, regulatory barriers, and growth potential tied to water-quality needs in healthcare and commercial settings. At the same time, the company’s recent commentary on tariffs and supply-chain conditions highlights exposure to input-cost pressure and execution risk. Overall, Nephros remains a small-cap Nasdaq-listed company with a specialized franchise and a recent operating momentum that may support investor interest, provided one accepts the risks typical of smaller, niche industrial-healthcare businesses. ([nasdaq.com](https://www.nasdaq.com/press-release/nephros-announces-fourth-quarter-and-record-fiscal-year-2025-financial-results-2026?utm_source=openai))